Loading stock data…
Revolution Medicines, Inc. (RVMD)
$207.32-2.70 (-1.29%)
Market ClosedLast close Sep 8
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Revolution Medicines, Inc. in the Healthcare sector is trading at $207.32 with a market capitalization of $44.4B. Wall Street consensus targets $250.46 (20 analysts), implying a +20.8% move over the next 12 months. The stock is currently near its 52-week high of $224.31, remaining 54.6% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$505.13M↓ | -$445.22M↓ | -$361.63M↓ | -$315.27M↓ | -$264.71M |
| Net Income | -$644.37M↓ | -$453.82M↓ | -$364.89M↓ | -$305.21M↓ | -$247.79M |
Peer Comparison
JNJUNHPFE
Fundamentals
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as m...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$44.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.41
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-67.85%
Volume
Today's trading volume
2.39M
Recent News
Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval
Revolution Medicines has delivered very large share price gains over the past few years, while broad valuation checks currently suggest the stock leans expensive rather than offering clear value. For investors, the question is how to balance that strong share price history against what the recent valuation signals are implying today. Over the past 5 years, Revolution Medicines has returned about 6x, which sets a high bar for any further upside from here. The recent FDA approval for Rasonque...
Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal
Revolution Medicines (NasdaqGS:RVMD) reported US FDA approval of RASONQUE for adults with previously treated metastatic pancreatic adenocarcinoma, the first broad RAS targeted therapy for this cancer type. RASONQUE is the first approved therapy from a new class of RAS(ON) multi selective inhibitors aimed at tumors driven by RAS mutations. Phase 1/2 clinical data for RASONQUE in RAS mutant non small cell lung cancer were published in the New England Journal of Medicine, providing independent...
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?
Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review. The once-daily oral RAS inhibitor is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Revolution Medicines, Inc. (NASDAQ:RVMD) set a wholesale acquisition cost (WAC) […]
Revolution Medicines Got Its Breakthrough—What Moves It Next?
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.